# NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors

> **NCT07664176** · PHASE1 · RECRUITING · sponsor: **Children's National Research Institute** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
- High Grade Gliomas
- Medulloblastoma Recurrent
- Ependymoma Recurrent
- Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS
- Brain Tumor Recurrent

## Interventions

- **DEVICE:** NeuroNavigation-Guided Focused Ultrasound (NgFUS)
- **DRUG:** Lumason
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT07664176
- **Lead sponsor:** Children's National Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07664176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07664176, "NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07664176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*